Project Grant R01CA295739
Award Date 8/25/25
Completion Date 7/31/30
Dollars Obligated $495K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
- This $533,707 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate how high-risk human papillomavirus (HPV) infection leads to cancer. The primary awardee, Trustees of Tufts College (doing business as Tufts University School of Medicine), will examine how the HPV E7 protein disrupts the balance between cell proliferation and differentiation in stratified...
- This Project Grant award, totaling $6,319,992, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The award supports research by Trustees of Tufts College, doing business as Tufts University School of Medicine, to investigate how human papillomavirus (HPV) E7 proteins reprogram host cell signaling pathways to facilitate viral replication and persistence. The research aims to...
- The National Cancer Institute (NCI) awarded a $544,250 project grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Nebraska Medical Center (UNMC) to investigate the immune drivers of oral human papillomavirus (HPV) persistence and progression to oropharyngeal cancer, particularly among people living with HIV. The grant, awarded on August 4, 2025, will fund research utilizing genome-wide DNA methylation analysis to determine the association between the host's...
- The University of New Mexico Health Sciences Center (UNM HSC) was awarded a $544,768 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research federal grant program (CFDA 93.396). The grant supports comprehensive research to understand the fundamental biological mechanisms underlying human papillomavirus (HPV)-related cancers, with a focus on investigating how inhibition of the MEK signaling pathway can lead to tumor regression. Key objectives include...
- The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, awarded a $660,205 Project Grant to The University of Texas Southwestern Medical Center to develop small molecule inhibitors targeting the bromodomain-containing protein 4 (BRD4) to block human papillomavirus (HPV) genome replication. The grant aims to identify and characterize compounds that can effectively inhibit the three stages of HPV DNA replication by targeting the phosphorylated...
- This Project Grant award, valued at $230,250.00 and provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), supports research into the mechanisms of how human papillomavirus (HPV) is transported within host cells after initial infection. The research project, conducted by the Board of Regents of the University of Nebraska's University of Nebraska Medical Center (UNMC), aims to investigate the role of the dynein motor protein...
- This Project Grant award of $510,650, funded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), supports research to investigate the biological factors driving clinical outcomes in HPV-positive oropharyngeal cancer (OPSCC) at Case Western Reserve University. The research aims to provide insights into how HPV status, HPV genotype, and the tumor-immune microenvironment may contribute to the observed differences in survival rates among OPSCC patient populations. The 5-year...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $630,506 to The Johns Hopkins University to develop and test a therapeutic vaccine against cervical cancer associated with variants of the human papillomavirus type 16 (HPV16). The primary goals are to: 1) characterize how different HPV16 variants evade immune system detection, 2) study the growth and tumor microenvironment of spontaneous cervical/vaginal cancers driven by HPV16...
- The University of North Carolina at Chapel Hill received a $688,458 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The award, which runs from September 15, 2025 to August 31, 2030, will investigate the use of 5-Fluorouracil (5FU) as an adjuvant therapy following thermal ablation to improve human papillomavirus (HPV) treatment outcomes among women living with HIV in Kenya. The study aims to evaluate the...
- This Project Grant award of $170,409 was provided by the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program, to the University of Texas Health Science Center at Houston (UTHealth). The purpose of the project is to examine the prevalence of human papillomavirus (HPV) and HPV-related cancer prevention behaviors among people experiencing homelessness in the United States from 2006-2018. The research will use a behavioral...